HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Clearblue estimates weeks, Barry Meltzer dies, P&G eliminating phthalates and triclosan, NPLEx adds Delaware

This article was originally published in The Tan Sheet

Executive Summary

P&G Clearblue pregnancy test estimates week of conception; AHPA co-founder Meltzer dies; P&G to eliminate phthalates, triclosan; CSPI, Aloe Science Council square off; Delaware joins NPLEx; IADSA focuses on supplement safety guidelines; Pharmavite expands Alabama facility.

You may also be interested in...

Herbalife Investments Streamline Supply Chain, Attract Industry Talent

Herbalife’s “seed-to-feed” vertical integration strategy includes a $130 million facility in North Carolina to open in 2014 and the continued recruitment of dietary supplement scientific and regulatory experts. The multilevel marketer also is deploying novel modes of product distribution across its markets.

J&J Trims Formaldehyde-Releasing Chemicals In Personal Care Items

In response to consumer demand, J&J will remove controversial ingredients from both baby and adult brands, including Aveeno, Clean & Clear, Lubriderm and Neutrogena.

Aloe, Cascara Sagrada Safety In Laxatives Still Needs Supporting Data – FDA

Data on aloe and cascara sagrada from the German Commission E monographs, World Health Organization reviews and the National Toxicology Program are insufficient to support the safety and efficacy of the ingredients in OTC laxatives, FDA concludes in a July 3 letter to the American Herbal Products Association


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts